Tweets
@lastwalsh @KyleWalkerM @RheumNow Second question: do you ever give a PEXIVAS-standard style steroid taper?
I'm 100% in agreement that we should favor PEXIVAS over observational data in most cases
In practice it seems like some patients need a bit more immunosuppression, though
Curious to hear your thoughts!
Mike Putman @EBRheum ( View Tweet )
2 years 7 months ago
#Infection rates are equal in #RWD #real #world #data using #biosimilars compared to previous use of #originators. BC database #0970 #ACR23 @RheumNow @ACRheum #arthritisresearchcanada #ARC https://t.co/eVSPgVfmQG
Janet Pope ( View Tweet )
2 years 7 months ago
#ACR23 Abs #2199 large RL study: SEC retention rates after 4 yrs approx. 50% in axSpA and PsA pts. Bio-naïve pts had higher retention, remission & response rates than pts with prior b/tsDMARD exposure, particularly in axSpA. https://t.co/Eq5BwILK3D @rheumnow https://t.co/slho6yAwtQ
Dr. Rachel Tate ( View Tweet )
2 years 7 months ago
SPARTAN referral recommendations for axSpA #ACR23 Abs #2214 https://t.co/VQedpNynpv support Abs #2207 https://t.co/8RB0D4ef7i findings discussing that non-rheums are less aware of IBP components/asking about them in CBP pts. @rheumnow https://t.co/23oUONsMfb
Dr. Rachel Tate ( View Tweet )
2 years 7 months ago
The presence of antibodies to 4 UH-axSpA peptides was confirmed in the Belgian Inflammatory Arthritis and Spondylitis (Be-Giant) cohort of newly diagnosed axSpA patients and could be of added value for axSpA diagnosis. #ACR23 Abs #2210 https://t.co/fV4PPbWF01 @rheumnow
Dr. Rachel Tate ( View Tweet )
2 years 7 months ago
1-PJP prophylaxis or not in ANCA?
2-MTX single dose or split dose?
3-IL6 blocker early on in GCA/PMR?
4-SGLT2 in DM/Lupus nephritis?
5-Cervical cancer screening in Lupus?
6-TNF induced ILD?
https://t.co/mzGXajmQqE
@RheumNow , Daily recap
#ACR23
Nouf Al hemmadi ( View Tweet )
2 years 7 months ago
PtGA and PhGA were aligned in most encounters in PsA. PtGA >PhGA disagreement was driven by pain, fatigue, and physical health being weighed more by Pts than Phs. PROs matter! #ACR23 Abs #2234 https://t.co/0r7gjx0JS6 @rheumnow https://t.co/BuGDicwBiB
Dr. Rachel Tate ( View Tweet )
2 years 7 months ago
Watch: Lupus and the Patient Perspective
Dr. Kathryn Dao talks with patient advocate Amanda Greene about her patient poster (PP03) on "Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime" at #ACR23.
https://t.co/JKU3w7sz4j https://t.co/IWHLJEi0qG
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
C9n @RheumNow, excelente persona. Gracias!! https://t.co/pGZnMHApQH
José Navia Dongo ( View Tweet )
2 years 7 months ago
Crude drug retention at 1 year was 65% for JAKi, significantly lower than for other modes of action (74%) and TNFi (77%). These results are driven by the severity of the disease of patients on JAKi compared to other MOA. Aymon R Abst#1692 #ACR23 @RheumNow https://t.co/LPDpWdjoLg https://t.co/Ztaz94omd9
Dr. Antoni Chan ( View Tweet )
2 years 7 months ago
Obs study, bDMARDs & malignancy
TNFi w/lower risk than ABA/RTX/IL6i & numerically lower than JAKs
I'm a little skeptical... KM curves diverged w/~45 days, seems implausible?
Agree w/first author, possible channeling bias
@RheumNow #ACR23 Abstr 1678 https://t.co/1uL3j6kTSj
Mike Putman @EBRheum ( View Tweet )
2 years 7 months ago
Sendaydiego et al. Comparative cancer safety b/tsDMARDs. 37,026 patient database cohort study. Compared to TNFi, RTX HR 2.2 (1.5, 3.3) ABA HR 1.7 (1.3-2.4), JAKi HR 1.3 (0.9-1.9). Abstr#1678 #ACR23 @RheumNow https://t.co/bTNtaNJrln https://t.co/qQBM2F2q8N
Richard Conway ( View Tweet )
2 years 7 months ago
